CH3 Biosystems

CH3 Biosystems is a biotechnology company specializing in innovative, patent-protected chemical technologies designed to support drug and diagnostic development. The company focuses on advancing research in protein methylation, which is a critical area in understanding diseases like cancer, autoimmune disorders, neurodevelopmental conditions, and cardiovascular diseases. Based in Amherst, New York, CH3 Biosystems offers a range of products, including methylation-specific antibodies, cell lines, enzymes, peptides, and vectors, which are used in biomedical research and therapeutic development.

CH3 Biosystems was co-founded by Dr. John M. Aletta, his wife Dr. Elaine Aletta, Dr. Walter A. Scott, and Dr. Robert A. Casero Jr.

Elaine Aletta is also actively involved in the company’s activities and contributes to its management and vision.

Their flagship product, the anti-mRG antibody, is designed to identify a wide range of methylproteins, aiding in the exploration of protein methylation pathways. CH3 BioSystems aims to drive advancements in diagnostics and pharmaceuticals through innovative molecular tools, contributing to research that addresses diseases affecting millions worldwide.

Search for products by CH3 Biosystems

CH3 Biosystems products by Product Category

• 
  Antibodies
• 
  Cell Lines & Cell Culture
• 
  Inhibitors & Compound Libraries
• 
  Nucleic Acids
• 
  Peptides & Proteins
• 
  Reagents & Chemicals
• 
  All Products